Curasan AG, company listed in the General Standard of the German Stock Exchange, has signed an agreement with Stryker S.A., Montreux, Switzerland, to sell and market bone replacement and regeneration materials for different orthopaedic indications.
Starting summer 2011, Stryker anticipates launching the products in selected European countries to be potentially followed by further target markets.
“Partnering with Stryker, a powerful global leader with experience in biologicals and biomaterials, opens up the highest-volume market segment for us, namely, orthopaedics”, stated Hans Dieter Rössler, CEO, Curasan.
David Halliday, VP Spine, Stryker, similarly expressed his satisfaction with the new partnership: “Once Stryker Europe decided to commit to focusing its sales efforts on the high-growth biomaterials market, the joint venture with Curasan was an excellent strategic match.”
The two corporations are planning a long-term collaboration and the possible inclusion of future pipeline products from Curasan AG in the agreement.